"We are very pleased with the appointment of these highly experienced healthcare industry executives. AMT is at an important juncture with the EMA for the marketing authorization of Glybera(R), which gears us up for the launch of the first gene therapy treatment in the Western world. The knowledge and experience that our new board members will contribute during this phase, and as we progress our pipeline further, will be highly valuable to the Company," said Ferdinand Verdonck, Chairman of the Supervisory Board.
Jorn Aldag, Chief Executive Officer of AMT, said: "We are proud to welcome these leaders of the life sciences industry to our Supervisory Board. Under our Chairman's leadership we now have an extraordinarily strong Supervisory Board that also includes Mr. Philippe van Holle, President of Celgene Europe, and co-founder of AMT, Sander van Deventer, Ph.D. With their knowledge and guidance, we are confident that we can realize our ambition to develop AMT into a full-fledged specialty pharmaceutical company."
Background new Supervisory Board members
Joseph M. Feczko, M.D.
Joseph Feczko was, until May, 2009, Senior Vice President and Chief Medical Officer (CMO) of Pfizer, Inc., and a member of the Executive Leadership Team with global responsibilities for all aspects of Pfizer's medical, regulatory and safety activities. Following a time in private practice, he joined Pfizer in 1982 in New York. He then worked for ten years in the United Kingdom for both Pfizer and Glaxo where his responsibilities included supervising clinical research, regulatory affairs, data management and safety reporting. He returned to Pfizer in New York in 1996, where he held positions of increasing responsibility in clinical research, and regulatory affairs and safety, culminating in the role of CMO.
Dr. Feczko is
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2010 PR Newswire.
All rights reserved